Pure Global
NCT06122649

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast 30 mg Twice Daily in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
Amgen·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
apremilast
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Amgen
Location
Beijing,Guangzhou,Shijiazhuang,Wuxi,Nanchang,Hangzhou,Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Nov 27, 2023
End date
Dec 24, 2025
Enrollment
200 participants
Primary outcome

Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16

Summary

The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with
 placebo in Chinese participants with moderate to severe PsO

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06122649
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06122649 through Pure Global AI's free database. This Phase 3 trial is sponsored by Amgen and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.